Ozone Pharmaceuticals expects revenue growth of at least 25% by the end of 2025, which is above the 10-15% growth forecast for the pharmaceuticals market. Capital investments will amount to ₽3.5-4.5 bln. Main investments will be made in the registration of biotechnological drugs. At the same time, the debt load is planned to remain in the range of 1-1.5x net debt/EBITDA and continue quarterly dividend payments.